The association between osimertinib therapy and EphB4 also demonstrates that osimertinib decreased the expression of EphB4 and that the knockdown of EphB4 reduced the sensitivity of osimertinib in lung carcinoma cell lines regardless of the EGFR mutation status. This evidence concerns the gene EGFR and lung carcinoma.